MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL) Files An 8-K Other Events
On May24, 2017, Miragen Therapeutics, Inc., a Delaware
corporation, or the Company, issued a press release announcing
that the European Commission granted orphan medicinal product
designation to the Companys product candidate, MRG-106, for the
treatment of cutaneous T-cell lymphoma. A copy of the press
release is filed as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.
|Item9.01||Financial Statements and Exhibits.|
|99.1||Press release, dated May 24, 2017.|
About MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL)
Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company’s clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110. MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL) Recent Trading Information
MIRAGEN THERAPEUTICS, INC. (NASDAQ:SGNL) closed its last trading session 00.00 at 12.30 with 38,761 shares trading hands.